Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 101 to 110 of 628 total matches.
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
obstructive pulmonary disease
1. Adult and pediatric patients (≥12 years old and weighing ≥40 kg) with ≥1 ...
In February 2021, the FDA issued an Emergency Use
Authorization (EUA) for the investigational monoclonal
antibodies bamlanivimab and etesevimab (Lilly) for
use together to treat mild to moderate COVID-19
in persons ≥12 years old who weigh ≥40 kg and
are at high risk of progression to severe disease or
hospitalization. The FDA has now expanded this
EUA to allow use of the antibodies together for post-exposure
prophylaxis of COVID-19 in such persons
if they are not fully vaccinated against COVID-19 or
are unlikely to have an adequate immune response
to full vaccination and have...
Penbraya: A Pentavalent Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Mar 18, 2024 (Issue 1698)
, and Y (MenACWY; Menveo, MenQuadfi)1 and
two meningococcal serogroup B vaccines (MenB;
Bexsero ...
The FDA has licensed Penbraya (Pfizer), a pentavalent
polysaccharide conjugate meningococcal
vaccine, for prevention of invasive meningococcal
disease caused by Neisseria meningitidis
serogroups A, B, C, W, or Y (MenABCWY) in persons
10-25 years old. Penbraya is the only meningococcal
vaccine that contains all five of these serogroups.
Two quadrivalent polysaccharide conjugate
meningococcal vaccines containing serogroups A,
C, W, and Y (MenACWY; Menveo, MenQuadfi) and
two meningococcal serogroup B vaccines (MenB;
Bexsero, Trumenba) are available in the US (see
Table...
Med Lett Drugs Ther. 2024 Mar 18;66(1698):43-5 doi:10.58347/tml.2024.1698b | Show Introduction Hide Introduction
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine
The Medical Letter on Drugs and Therapeutics • May 17, 2021 (Issue 1624)
impairment. Rates of
meningococcal disease are highest in infants ...
The FDA has licensed MenQuadfi (Sanofi Pasteur),
a quadrivalent polysaccharide conjugate vaccine
that uses tetanus toxoid as a protein carrier, for
prevention of invasive meningococcal disease caused
by Neisseria meningitidis serogroups A, C, W, and Y
(MenACWY) in persons ≥2 years old.
FDA Authorizes Moderna COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
on December 11, 2020.1
CLINICAL STUDY — Issuance of the EUA was based
primarily on the results ...
On December 18, 2020, the FDA issued an Emergency
Use Authorization (EUA) for the Moderna mRNA-based
vaccine for prevention of COVID-19 in persons
≥18 years old. The Pfizer-BioNTech mRNA-based
vaccine received an FDA EUA for the same indication
in persons ≥16 years old on December 11, 2020.
In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
for the same indication.1 Kimyrsa has a smaller
infusion volume (250 mL vs 1 L) and a shorter infusion
time ...
The FDA has approved Kimyrsa (Melinta), a new
IV formulation of the long-acting lipoglycopeptide
antibiotic oritavancin, for treatment of adults with acute
bacterial skin and skin structure infections caused by
susceptible gram-positive bacteria. Orbactiv (Melinta),
another IV formulation of oritavancin, was approved in
2014 for the same indication. Kimyrsa has a smaller
infusion volume (250 mL vs 1 L) and a shorter infusion
time (1 hour vs 3 hours) compared to Orbactiv (see
Table 1).
Vaccination Recommendations for Updated 2024-2025 COVID-19 Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
: Three doses: 1st at week 0, 2nd at week 3-8, and 3rd ≥8 weeks after dose 25
1 previous Pfizer dose: One ...
View the Vaccination Recommendations for Updated 2024-2025 COVID-19 Vaccines
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e1 doi:10.58347/tml.2025.1723g | Show Introduction Hide Introduction
Drugs for Acne
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024 (Issue 1695)
in 2016.1
PATHOGENESIS
The pathogenesis of acne is multifactorial: follicular
hyperkeratinization ...
Acne is common among adolescents and adults.
Guidelines for treatment of acne were last published
by the American Academy of Dermatology in 2016.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):17-20 doi:10.58347/tml.2024.1695a | Show Introduction Hide Introduction
Molnupiravir - An Oral Antiviral Drug for COVID-19
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
of progressing to severe disease, including
hospitalization or death (see Table 1), and for whom
alternative ...
The investigational oral antiviral drug molnupiravir
(Merck/Ridgeback Biotherapeutics) was granted an
FDA Emergency Use Authorization (EUA) on December
23, 2021 for treatment of mild to moderate COVID-19
in outpatients ≥18 years old who are at high risk of
progressing to severe disease, including hospitalization
or death (see Table 1), and for whom alternative treatment options are
not available or clinically appropriate. Paxlovid (Pfizer),
nirmatrelvir copackaged with ritonavir, was granted
an EUA on December 22, 2021. The IV antiviral drug
remdesivir (Veklury) was approved by the...
Erdafitinib (Balversa) for Urothelial Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death ...
Erdafitinib (Balversa – Janssen), an oral kinase
inhibitor, has received full approval from the FDA
for treatment of locally advanced or metastatic
urothelial carcinoma in adults with susceptible
FGFR3 (fibroblast growth factor receptor) genetic
alterations who had disease progression on or after
at least one prior line of systemic therapy. It is not
recommended for use in patients who are eligible
for but have not received prior PD-1 (programmed
death receptor-1) or PD-L1 (programmed death-ligand
1) inhibitor therapy. Erdafitinib is the first
oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4 doi:10.58347/tml.2024.1702g | Show Introduction Hide Introduction
In Brief: Retifanlimab (Zynyz) for Merkel Cell Carcinoma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA ...
Retifanlimab-dlwr (Zynyz – Incyte), a programmed
death receptor-1 (PD-1) blocking antibody, has
received accelerated approval from the FDA for
treatment of metastatic or recurrent locally advanced
Merkel cell carcinoma (MCC) in adults. Accelerated
approval of the drug was based on the response rate
and duration of response. Retifanlimab is the third
drug to be approved in the US for treatment of MCC;
pembrolizumab (Keytruda), a PD-1 blocking antibody,
is approved for the same indication as retifanlimab
in patients ≥12 years old and avelumab (Bavencio),
a programmed death...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e73-4 doi:10.58347/tml.2023.1674h | Show Introduction Hide Introduction